Article info
PDFEditors’ commentary
Highlights from this issue
Citation
Highlights from this issue
Publication history
- Accepted April 25, 2022
- First published May 17, 2022.
Online issue publication
May 17, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review
- Convexity subarachnoid haemorrhage: a practical guide
- Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease
- Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis
- Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations
- Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years?
- Infectious encephalitis: mimics and chameleons
- Cerebral amyloid angiopathy related inflammation: three case reports and a review
- Tumour-like presentation of atypical posterior reversible encephalopathy syndrome with prominent brainstem involvement
- Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination